AbbVie
$262.82Change from previous close: +1.11%Absolute change: +$2.89
At a glance
- Revenue growth
- +8.57%
- 2025 vs 2024
- Net income growth
- −1.22%
- 2025 vs 2024
- Net margin
- 6.9%
- 2024: 7.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 19,030 | 18,806 | 22,839 | 24,943 | 22,777 | 17,588 | 13,324 | 13,427 | 9,960 | 7,041 |
| Depreciation and amortization | 8,139 | 8,386 | 8,698 | 8,467 | 8,521 | 6,471 | 2,017 | 1,765 | 1,501 | 1,189 |
| Capital expenditure | -1,214 | -974 | -777 | -695 | -787 | -798 | -552 | -638 | -529 | -479 |
| Investing cash flow | -6,643 | -20,820 | -2,009 | -623 | -2,344 | -37,557 | 596 | -1,006 | -274 | -6,074 |
| Financing cash flow | -12,724 | -5,211 | -17,222 | -24,803 | -19,039 | -11,501 | 18,708 | -14,396 | -5,512 | -3,928 |
| Dividends paid | -11,657 | -11,025 | -10,539 | -10,043 | -9,261 | -7,716 | -6,366 | -5,580 | -4,107 | -3,717 |
| Share repurchases | -980 | -1,708 | -1,972 | -1,487 | -934 | -978 | -629 | -12,014 | -1,410 | -6,033 |
| Debt issued | 9,291 | 21,971 | 0.0 | 2,000 | 1,000 | 3,000 | 31,482 | 9,264 | 23.0 | 11,627 |
| Debt repaid | -9,595 | -14,621 | -4,149 | -14,433 | -9,414 | -5,683 | -5,235 | -6,035 | -25.0 | -6,033 |
| Effect of exchange rates | 42.0 | -65.0 | 5.0 | -62.0 | -97.0 | -5.0 | 7.0 | -39.0 | 29.0 | -338 |
| Net change in cash | -295 | -7,290 | 3,613 | -545 | 1,297 | -31,475 | 32,635 | -2,014 | 4,203 | -3,299 |
| Free cash flow | 17,816 | 17,832 | 22,062 | 24,248 | 21,990 | — | — | — | — | — |
| Levered free cash flow | 18,338 | 19,409 | 22,975 | 21,261 | 19,394 | 16,222 | 8,763 | 12,412 | 6,216 | 5,525 |